[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"b-cell-lymphoma-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:b-cell-lymphoma-recurrent":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,74,106,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100558549","phase-1-selinexor-with-ice-chemotherapy-in-secondary-central-nervous-system-involving-b-cell-non-hodgkin-lymphoma-100558549",false,"NCT06552559","Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma","Phase 1\u002F2 Study of Selinexor With Dexamethasone, Ifosfamide, Carboplatin, and Etoposide in Patients Who Have Secondary Central Nervous System Involvement With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","SIENA","Inclusion Criteria:\n\n* Patients must have histologically confirmed B-cell NHL with CNS involvement DLBCL including ABC, GCB or PMBCL subtypes Indolent lymphomas transformed to aggressive lymphomas Follicular lymphomas\n* Patients must have received at least one cycles of anthracycline based chemotherapy administered with curative intent\n* Patients must be age ≥18 years.\n* Patients must have at least one site of measurable disease, 1.5 cm in diameter or greater.\n* Patients must have ECOG performance status of 0-2.\n* Patients must have laboratory test results within these ranges: Absolute neutrophil count ≥ 1500\u002Fmm³, Platelet count ≥ 100,000\u002Fmm³, Serum creatinine clearance ≥40 mL\u002Fmin, Total bilirubin ≤ 1.5x ULN (Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis.), AST (SGOT) and ALT (SGPT) ≤ 2x ULN\n* Women of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test prior to selinexor treatment. Male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential.\n* Patients must be able to understand and willing to sign a written informed consent document.\n* Patients must be able to adhere to the study visit schedule and other protocol requirements.\n* Patients must not have any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.\n* Patients must not have any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he\u002Fshe were to participate in the study or confounds the ability to interpret data from the study.\n* Patients with hepatitis B virus including HBsAg-positive carrier or IgG anti- HBc-positive can be enrolled if they can receive anti-viral prophylaxis\n\nExclusion Criteria:\n\n* Patients cannot fulfill the above-mentioned inclusion criteria\n* Patients with primary CNS lymphoma\n* Patients with a prior history with selinexor","ALL","18 Years",{"count":20,"type":21},37,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Secondary involvement of the central nervous system (CNS), such as CNS relapse after treatment or progression during treatment, is a rare but deadly occurrence in patients with B-cell non-Hodgkin lymphoma (NHL), particularly in cases of diffuse large B-cell lymphoma (DLBCL) and transformed follicular lymphoma (FL). Despite the grim prognosis associated with secondary CNS involvement, no definitive treatment strategy exists. Selinexor®, an oral, first-in-class, potent selective inhibitor of nuclear export that binds to XPO1, leads to the nuclear retention of tumor suppressor and growth regulator proteins, as well as topoisomerase II enzymes, thereby restoring their functions. Preclinical studies have also shown that selinexor can sensitize cancer cells to topoisomerase inhibitors, alkylating agents, and steroids. Selinexor has been approved by the Food and Drug Administration for relapsed or refractory DLBCL. We hypothesize that selinexor could work synergistically with ifosfamide (an alkylating agent) and etoposide (a topoisomerase II inhibitor) in the ifosfamide, carboplatin, and etoposide (ICE) regimen. High-dose dexamethasone was added to this regimen to enhance the efficacy of ICE as a salvage regimen for secondary CNS involvement, due to its ability to cross the blood-brain barrier.\n\nThis phase I\u002FII study aims to evaluate the efficacy and safety of selinexor in combination with ifosfamide, carboplatin, etoposide (ICE), and dexamethasone in patients with relapsed or refractory B-cell non-Hodgkin lymphoma with secondary CNS involvement.",[28,29,30],"B-cell Lymphoma Recurrent","B-cell Lymphoma Refractory","CNS Metastases",[32,33,34,35],"Non-Hodgkin B-cell lymphoma","Secondary CNS involvement","Selinexor","ICE","RECRUITING","2026-04-22",{"date":39,"type":40},"2026-04-23","ACTUAL",{"date":42,"type":40},"2024-05-01",{"date":44,"type":21},"2028-12-30",{"name":46,"class":47},"Samsung Medical Center","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100545153","phase-1-treatment-of-relapsed-or-refractory-b-cell-lymphoma-with-chimeric-antigen-receptor-car-t-cell-therapy-produced-by-a-new-technology-100545153","NCT06378190","Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology","Multicentre Phase I\u002FIIa Study of Infusion of Autologous Peripheral Blood T Lymphocytes Expanded and Genetically Modified Using Sleeping Beauty Family Transposons to Express a Chimeric Antigenic Receptor With Anti-CD19 Specificity Conjugated to the 4-1BB Co-stimulatory Region and CD3z and huEGFRt Signal Transmission (TranspoCART19) in Patients With Relapsed or Refractory B-cell Lymphoma","TranspoCART19","Inclusion Criteria:\n\n1. Patients diagnosed with relapsed or refractory B-cell lymphoma (Diffuse large B-cell lymphoma, Primary diffuse large B-cell lymphoma of the Central Nervous System (CNS), Mantle cell lymphoma, Follicular lymphoma grades 1, 2 or 3a or Marginal lymphoma, including splenic, nodal and MALT).\n2. Age over 18 years and under 80 years.\n3. Functional status Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. Patients with ECOG 2 may be included if motivated by haematological disease (Annex 3).\n4. Adequate bone marrow haematopoietic reserve.\n5. Life expectancy of at least 2 months.\n6. Adequate venous access for lymphapheresis. Absence of contraindications for lymphapheresis.\n7. Signed informed consent (patient or legal guardian).\n\nExclusion Criteria:\n\n1. Patients who, in the opinion of a physician, may benefit from other approved potentially curative therapeutic options, including commercial CAR-Ts.\n2. Treatment with any experimental or non-commercialised substance in the four weeks prior to recruitment, or who are actively participating in another therapeutic clinical trial.\n3. Diagnosis of another neoplasm, past or present. Patients who have been in complete remission for more than 3 years, or with a history of non-melanoma skin cancer or completely resected carcinoma in situ may be included. A current or previous history of clonal T-lymphocytes is also an exclusion criterion.\n4. Early relapse after allogeneic haematopoietic stem cell transplantation (less than 3 months for lymphapheresis, less than 6 months for TranspoCART19 infusion) or patients on active immunosuppressive treatment for graft-versus-recipient disease (corticosteroids or other systemic immunosuppressants).\n5. Active infection requiring systemic medical treatment.\n6. HIV infection.\n7. Concurrent and uncontrolled medical illnesses including cardiac, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological or psychiatric illnesses that in the opinion of the investigator pose a risk to the patient.\n8. Positive serology for hepatitis B, defined as a positive test for HBsAg. In addition, if the patient is HBsAg negative but has anti-HBcore antibodies, a hepatitis B virus DNA test will be required, and if the result is positive the patient will be excluded.\n9. Positive serology for hepatitis C virus (HCV), defined as a positive test for anti-HCV antibodies that is confirmed by Recombinant immunoblot assay (RIBA).\n10. Severe organ involvement, defined as cardiac ejection fraction \\\u003C40%; diffusing capacity of the lungs for carbon monoxide (DLCO) \\\u003C40%; calculated glomerular filtration rate \\\u003C30 ml\u002Fmin; baseline O2 saturation \\\u003C92%; bilirubin \\> 2 times upper limit of normal (unless due to Gilbert's syndrome) or transaminases \\> 2.5 upper limit of normal.\n11. Pregnant or lactating women. Women of childbearing age should have a negative pregnancy test at screening.\n12. Women of childbearing age, including those whose last menstrual cycle was in the year prior to screening, who are unable or unwilling to use highly effective methods of contraception\\* from the start of the study until the end of the study.\n13. Men who are unable or unwilling to use highly effective methods of contraception\\* from the start of the study until the end of the study.\n14. Need to take glucocorticoids chronically in doses greater than 10 mg\u002Fday of prednisone (or equivalent) or other chronic immunosuppressants.\n15. Previous anti-CD19 CAR-T therapy. Previous treatment with other anti-CD19 strategies is permitted, provided that CD19 expression has been confirmed in the tumour biopsy.\n16. Hypersensitivity to the active substance or to any of the excipients.","80 Years",{"count":59,"type":21},27,[24,25],"The goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed\u002Frefractory B-lymphoma. The main questions it aims to answer are:\n\nMaximum tolerated dose (MTD) Response rates Participants will be treated with the investigational medicinal product and will be followed for 36 months.",[63,28],"Refractory B-Cell Lymphoma","2026-04-13",{"date":66,"type":40},"2026-04-16",{"date":68,"type":40},"2024-03-11",{"date":70,"type":21},"2030-07",{"name":72,"class":47},"Instituto de Investigación Biomédica de Salamanca",8,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100493470","phase-1-clinical-trial-using-car--t-cells-for-treatment-of-patients-with-refractory-or-relapsed-cd19-positive-b-lymphoid-malignancies-100493470","NCT05705570","Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies","A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies","CARTHIAE-1","Inclusion Criteria:\n\n1. Subjects must have relapsed or refractory ALL, lymphoma or CLL treated with at least two lines of therapy. Disease must have either progressed after the last regimen or presented failure to achieve partial or complete remission with the last regimen.\n\n   Subjects with Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ALL) subjects are eligible if they progressed, had stable disease or relapsed after two lines of therapy, including tyrosine kinase inhibitors (TKIs).\n\n   Subjects with DLBCL must have progressed, had SD, or recurred after initial treatment regimens that include an anthracycline and an anti-CD20 monoclonal antibody.\n\n   Subjects with transformed FL, MZL, or CLL\u002FSLL must have progressed, had SD or recurred with transformed disease after initial treatment for DLBCL.\n\n   Subjects who relapse ≥12 months after therapy should have progressed after autologous transplant or been ineligible for autologous transplant.\n2. 2\\. The patient's disease must be CD19 positive, either by immunohistochemistry or flow cytometry analysis on the last biopsy available.\n3. Age 2 to 70 years.\n4. Performance status: Adult Subjects: ECOG ≤ 2 for patients ≥ 16 years; Subjects \\\u003C 16 years of age: lansky ≥ 50%\n5. Normal Organ and Marrow Functioning (supportive treatment is allowed according to institutional standards, i.e. filgrastim, transfusion)\n\n   • Total Bilirubin ≤ 2; AST (SGOT) ≤ 5 times the upper limit of normal; ALT (SGTP) ≤ 5 times the upper limit of normal; Serum creatinine ≤ 1.5; Pulse oximetry \\>91% on room air; No dyspnea or mild dyspnea (≤ Grade 1); Forced expiratory volume in 1 s (FEV1) ≥50% or carbon monoxide diffusion test (DLCO) ≥50% of predicted level; Left ventricular ejection fraction ≥ 45% confirmed by echocardiogram; Subjects must have the following hematologic function parameters: Neutrophils \\> 1000\u002FuL; Absolute Lymphocyte Count \\> 100\u002FuL; Platelets ≥ 50,000\u002FL Patient should not be excluded if change of the above parameters due to spinal cord disease infiltration;\n6. Prior therapy wash-out - At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory\u002Fstimulatory immune checkpoint therapy, which requires 5 half-lives, Blinatumomab with 4 months prior CAR-T infusion.\n7. For women of reproductive potential: use a highly effective contraceptive for at least 1 month prior to screening and agree to use a method during study participation and for an additional 4 months after CAR T-cell administration has ended.\n8. Subjects must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Autologous transplant within 6 weeks of planned CAR-T cell infusion;\n2. History of allogeneic stem cell transplant 4 months prior CAR T cell infusion.\n3. Use of immunosuppression therapy;\n\n   • Patients must have completed immunosuppression therapy; Systemic corticosteroid therapy must be stopped more than 72 hours after infusion; Systemic drugs for graft-versus-host disease should be withheld at least 4 weeks prior to infusion;\n4. Presence of graft-versus-host disease Grade ≥ 2;\n5. Receiving CAR T cell treatment outside of this protocol;\n6. Active central nervous system or meningeal involvement by tumor. Subjects with untreated brain metastases\u002FCNS disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal involvement must be in a documented remission by CSF evaluation and contrast-enhanced MRI imaging for at least 90 days prior to registration.\n7. History of active malignancy other than non-melanoma skin cancer, carcinoma in situ (e.g. cervix, bladder, breast).\n8. HIV infection; HTLV\n9. Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n10. Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects.\n11. Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy\n12. Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)\n13. Serious and\u002For potentially fatal medical conditions\n14. Patients with history of clinically relevant CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease.\n15. History of autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.\n16. Hypersensitivity against any drug or its ingredients\u002Fimpurities that is scheduled or likely to be given during trial participation, e.g. as part of the mandatory lymphodepletion protocol, pre-medication for infusion, rescue medication\u002Fsalvage therapies for treatment related toxicities;","2 Years","70 Years",{"count":85,"type":21},30,[24],"This is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL\u002FCLL (Cohort 3).",[89,90,28,29,91,92],"Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia Refractory","Chronic Lymphocytic Leukemia Recurrent","Chronic Lymphocytic Leukemia Refractory",[94,95],"CAR T cell","CD19+ B-cell Malignancies","2025-09-22",{"date":98,"type":40},"2025-09-25",{"date":100,"type":40},"2023-02-07",{"date":102,"type":21},"2028-12-01",{"name":104,"class":47},"Nelson Hamerschlak",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":48},"100550340","phase-1-cd19cd22-car-t-cells-in-adults-with-rr-all-or-nhl-100550340","NCT06445803","CD19\u002FCD22 CAR-T Cells in Adults With R\u002FR ALL or NHL","A Preliminary Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetic Profile of KQ-2002 (CD19\u002FCD22 CAR-T) in Adults With Recurrent or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma","Inclusion Criteria:\n\n* Male or female,≥18 years old;\n* Histologically confirmed diagnosis of B-ALL or B-NHL(meeting one of the following conditions):\n\n(B-NHL)\n\n1. Second or greater relapse (CD20 regimens must be included) OR\n2. Refractory to first-line chemotherapy or relapse within 1 year OR\n3. Relapse within 1 year of auto-HSCT.\n4. With measurable or evaluable lesions（Dose expansion cohort） (B-ALL)\n\na. Relapse within 12 months of complete remission on first treatment OR b. Relapse after second-line treatment OR c. Relapse after auto HST OR d. Failure to achieve CR\u002FCRi at the end of induction therapy OR e. Ph+ ALL intolerance to TKI or refractory or relapse after treatment with at least two and more TKIs.\n\n* ECOG 0\\~2\n* Estimated survival time ≥ 12 weeks;\n* Main tissues and organs function well.\n\nExclusion Criteria:\n\n* Subjects will be excluded related to the following prior therapy criteria:Prior treatment with bendamustine-containing or fludarabine;Anti-T-cell monoclonal antibody, donor lymphocyte infusion, and CNS radiotherapy within 8 weeks; Chemotherapy, lenalidomide, bortezomib within 2 weeks; vincristine within 1 week; glucocorticoids (prednisone ≥7.5 mg\u002Fd or equivalent) within 72 h\n* Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening\n* Uncontrolled, symptomatic, intercurrent illness including but not limited to angina pectoris, cerebrovascular accident or transient ischemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), New York Heart Association (NYHA) classification of ≥ Class III congestive heart failure, severe arrhythmia poorly controlled by medications, hepatic, renal, or metabolic disorders, and hypertension that is uncontrolled by standard therapy；\n* active bleeding, or venous thromboembolic event\n* Autoimmune diseases (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.) that result in end-organ damage or require systemic application of immunosuppressive drugs\n* Central nervous system (CNS) disease or symptoms of CNS involvement\n* Pregnant or nursing (lactating) women\n* Presence of Grade 2 or above non-hematologic toxicity , alopecia and grade 2 neuropathy excluded\n* Any Iinappropriate conditions in the opinion of the PI .",{"count":114,"type":21},48,[24],"This study examines the safety, tolerability and preliminary efficacy of anti-CD19 \u002FCD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.",[89,118,29,28],"Acute Lymphoblastic Leukemia With Failed Remission",[120],"CAR-T therapy","2024-06-01",{"date":123,"type":40},"2024-06-06",{"date":125,"type":40},"2024-05-31",{"date":127,"type":21},"2026-12",{"name":129,"class":47},"Rong Tao",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":105},"100509105","phase-1-safety-and-efficacy-of-autologous-nk-cell-adjuvant-therapy-for-relapsedrefractory-non-hodgkins-b-cell-lymphoma-100509105","NCT05909098","Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed\u002FRefractory Non-Hodgkin's B-cell Lymphoma","Xiangyang No.1 People's Hospital, Hubei University of Medicine","Inclusion Criteria:\n\n1. Patients with age 15 years to 80 years, with life expectancy greater than 6 months.\n2. Pathologically confirmed non-Hodgkin B-cell lymphoma, confirmed by pathological examination at a grade A class 3 hospital or above, with pathology reported less than 3 years ago.\n3. First diagnosed relapsed\u002Frefractory non-Hodgkin's B-cell lymphoma.\n4. ECOG scores were 0 to 2\n5. Presence of at least one CT measurable lesion locus with a maximum transverse diameter of ≥1.5 cm before inclusion in the study.\n6. For women of childbearing potential, a negative pregnancy test must be confirmed before inclusion in the study and no intention to have children within 2 years.\n7. For men of childbearing potential, inform and require the use of an effective barrier contraceptive method.\n8. Volunteer to participate in the trial and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of bone marrow or\u002Fand central nervous system lymphoma.\n2. Patients with less than 5% peripheral blood NK cell percentage and pre-culture failure.\n3. Combined with other malignancies.\n4. Fever of non-disease-related origin within the last 5 days.\n5. Presence of uncontrollable bacterial, fungal, viral or other infections.\n6. Patients with HIV, TP positive\n7. Patients with severe cardiopulmonary, hepatic and renal, and cerebral dysfunction are present.\n8. Presence of other serious diseases that conflict with this protocol, such as autoimmune diseases, immunodeficiencies, severe thrombocytopenia, platelet dysfunction syndrome, etc.\n9. Received any form of organ transplantation, including allogeneic stem cell transplantation.\n10. Presence of a serious psychiatric disorder.\n11. Inability to communicate normally and incapacitation make it difficult to assess the safety and effectiveness of treatment.\n12. Pregnant or lactating women.\n13. The researchers deemed unsuitable for participation in this study. -",{"count":138,"type":21},33,[24,25],"This study was a single-arm trial of autologous NK cell adjuvant therapy for relapsed\u002Frefractory non-Hodgkin's B-cell lymphoma. The locations isXiangyang No.1 People's Hospital, Hubei University of Medicine. The population was relapsed\u002Frefractory non-Hodgkin's B-cell lymphoma. The sample size was 33. The intervention was R-GemOx regimen combined with autologous NK cells. The dose of autologous NK cells was body surface area x (2-4) x 109 cells. The course of treatment was once every 14 days. The primary outcome measure was ORR. The duration of assessment was for each treatment cycle, 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 3 years, and 5 years of treatment.",[142,28,29],"NK Cell","NOT_YET_RECRUITING","2023-06-19",{"date":146,"type":40},"2023-06-22",{"date":148,"type":21},"2023-07-01",{"date":150,"type":21},"2028-11-30",{"name":152,"class":47},"Xiangyang No.1 People's Hospital"]